Board of Directors
Mr. Allen co-founded RTI Biologics (Nasdaq:RTIX), a medical device company with proprietary technology in orthopedics and tissue regeneration, and led the company’s IPO in August 2000.
In addition to RTIX, he has co-founded several successful medical technology companies, including Axogen (Nasdaq:AXGN)(peripheral nerve regeneration), ViewRay (beam-on MRI-guided radiation therapy devices), OrthoHelix (small bone orthopedics), Optima Neuroscience (neural monitoring technology), RegisterPatient.com (cloud-based patient registration), and HyGreen (a spinoff company from Xhale that markets a novel electronic hand hygiene monitoring and reminding system).
Mr. Allen also co-founded Synogen, a private equity medical technology venture fund, and Emergent Growth Fund, a technology investment fund. He is a CPA and has served on the boards of numerous companies.
David Corddry has been a member of our Board since August 2014. Mr. Corddry is a certified public accountant.
Since 2005, Mr. Corddry has been the Chief Financial Officer for United Medical Corporation, comprising a diversified group of healthcare companies, including ownership and management of acute care and specialty hospitals. From 2004 to 2005, Mr. Corddry was a Division Controller for Invivo Corporation, a manufacturer of patient monitors and magnetic resonance imaging equipment. From 1998 to 2004, Mr. Corddry was a Division Controller for IKON Office Solutions, a provider of document management systems and services (which was purchased by Ricoh Company, Ltd. in 2008).
Mr. Corddry earned his bachelor’s degree in business at Michigan State University in 1989, his master’s degree of business from the Crummer School of Business at Rollins College in 1997, and his Bachelor of Science of Accounting at Florida Southern College in 2005. Mr. Corddry was chosen to serve on our Board as a result of his financial and accounting experience, as well as his management experience in the healthcare industry.
Mr. Harper has operated numerous successful medical technology companies in his entrepreneurial career. He was President and CEO of ATI Medical (implanted cobalt palladium rods to ablate cancers), which was funded by Domain Associates, Proquest Ventures and Johnson & Johnson Development Corp.
Prior to ATI he was Executive Chairman of Meretek Diagnostics (diagnostic breath tests using isotope labeled substrates), which was ultimately acquired by American Standard Companies. Mr. Harper also served as President and CEO of Índigo Medical (medical lasers), where he led a successful merger with Johnson & Johnson Ethicon EndoSurgery.
Mr. Harper was also President and CEO of Menlo Care (specialty vascular access and urology devices), which also merged into a division of Johnson & Johnson.
Mr. Johnson is an original investor and founding Board member of Xhale, Inc. He is a member of the family that founded Johnson and Johnson (NYSE:JNJ), and remains interested in translational, medical research and innovation.
Both a philanthropist and businessman who has distinguished himself in local, regional and national start ups, Mr. Johnson was a founder of the Somerset Valley Bank, a one-location bank started in a remodeled house in the County seat near the Johnson family home in New Jersey. From these humble beginnings, the bank grew to a regional chain, financial service firm, NASDAQ listing, and ultimately purchase by Fulton Financial. Mr. Johnson remained active on the BOD and Committees for over a decade.
He is a Florida resident who serves on the Board of Directors of the Benjamin School. Mr. Johnson regularly evaluates new technology and treatments when visiting the University of Florida. He helped fund the UF start up Viewray, a novel radiation oncology company formed after a McKnight Brain Institute scientific discovery and patent. Viewray has since moved from Gainesville to Cleveland and has received major investments from Orbimed, Fidelity and the State of Ohio as it prepares to bring its novel approach to cancer treatment to market this year.
Terence Mullervy has been a member of our Board since August 2014. Mr. Mullervy spent 34 years in international banking and finance. After graduating from the credit training program at the Chase Manhattan Bank in New York, he was sent on a variety of assignments over 14 years with the bank. He was a corporate lending officer, responsible for asset quality, product innovation and marketing in the Bank’s corporate finance units in Mexico City and London. He worked as an expat in those locations for over 10 years. During his time in London, Mr. Mullervy was an account officer and managed a section of the Commodity Division; arranging financing for European based trading houses. Aside from line assignments, Mr. Mullervy also held staff positions at the bank. He was an instructor in the Bank’s credit training program both in New York and Puerto Rico, teaching the curriculum, developing then leading case studies and mentoring the analysts. Towards the end of his career with Chase, Mr. Mullervy was the Chief of Staff to the head of the Bank’s Global Trading and Securities Sector. He was responsible for coordinating market analysis, product development and financial management units and provided daily briefings to the executive on sector wide issues. From there, Mr. Mullervy moved to the trading floor to become a crude oil trader for Chase.
In 1987 Mr. Mullervy was recruited by the privately held Swiss based trading house, Glencore A.G., as the Treasurer of Glencore Ltd. based in Stamford Ct. There he managed the treasury function of Glencore’s Western Hemisphere oil, metals and agri business operation including funding, investment, hedging , counterparty credit risk analysis and portfolio administration . In 1989, Mr. Mullervy was made a partner in Glecnore A. G. In 1998 Mr. Mullervy returned to London, this time as Finance Director for Glencore UK Ltd., where he managed all aspects of the finance, compliance and legal functions for Glencore’s worldwide oil business. While in this role, he raised capital on behalf of Glencore A. G. in over two dozen transactions from investors in the Euro, Asian and US markets. Mr. Mullervy was a Board member of Glencore UK Ltd, Glencore Commodities UK and was a member of the New York Mercantile Exchange. Mr. Mullervy retired as a partner of Glencore A. G. after more than 20 years with the firm. Since then he has been an active as a private investor in a number startup companies focused primarily on health care.
Mr. Spencer joined the Board of Directors in 2014. Mr. Spencer is a certified public accountant and was a partner of Ernst & Young LLP where he spent more than 38 years until he retired in 2000. Mr. Spencer serves as a Director of MRI Interventions, Inc. (Nasdaq: MRIC), a medical device company, where he also chairs the Audit Committee and serves on the Compensation Committee. He also serves as a Director of GeoVax Labs, Inc. (Nasdaq: GOVX), a vaccine development company, where he also chairs the Audit and Nominating & Governance committees and serves on the Compensation Committee. In addition, he also serves or has served on the Boards of Directors of several privately owned companies as chair of their Audit Committees. He served as the Temporary Chief Financial Officer of Applied Genetic Technologies Corporation from November 2013 until February 2014 while that company prepared for its initial public offering. He also serves as a consultant to various companies primarily relating to financial accounting and reporting matters. While at Ernst & Young LLP, he was the Partner in charge of that firm’s life sciences practice for the southeastern United States, and his clients included a large number of publicly-owned and privately-held medical technology companies. He served as Managing Partner of the Providence Office and was the Partner in charge of the audit departments at both the Boston and Atlanta offices. He also founded and/or served as a Director on several not-for-profit industry and civic organizations.
Mr. Spencer received a Bachelor of Science degree from Syracuse University and he earned an MBA degree at Babson College. In addition, he attended the Harvard Business School Advanced Management Program.
Nauman Toor joined the Xhale, Inc. Board in July of 2014. Since December 2012, Mr. Toor has served as a Partner and the Chief Investment Officer of Luzich Partners LLC, a multi-strategy investment firm, which he cofounded. Since January 2007, Mr. Toor has served as the chief investment officer of BlackRoot Capital, an investment fund focused on small-cap public equities and special situations, which he founded.
From 2001 to 2006, Mr. Toor served as Managing Director of Jefferies & Company Inc. (Jefferies), an investment bank. He served as Head of Media Investment Banking at Jefferies from 2002 to 2006, where he began working in 1994. During his tenure, Jefferies became the largest middle market focused investment bank in the country, with an increase in market value from $50 million to over $3 billion. Mr. Toor was promoted as the youngest Managing Director in the firm’s history and has led financing transactions in excess of $10 billion as well as M&A and restructuring arrangements in excess of $3 billion.
Mr. Toor started his career in investment banking with Kidder Peabody & Company, where he worked from 1990 to 1994. He has been Director of AVP Inc. since May 2008. Mr. Toor earned a Bachelor of Arts degree in Economics from Ohio Wesleyan University in 1990 and a Masters in Business Administration from Harvard Business School in 1994.